The FDA has delayed its licence decision on Novartis’ once-daily COPD treatment QAB149 by three months. The review process will …
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time

